UK medical cannabis experts have published a comprehensive review of evidence for the prescription of cannabis-based medicines in epilepsy.
With over 280 references to peer-reviewed literature, Medical Cannabis & Epilepsy, published by Maple Tree Consultants, provides the first review of nearly 100 clinical trials, real-world studies, and observational research on the role of Cannabis-Based Medicinal Products (CBMPs) in epilepsy management.
Co-written by Professor Mike Barnes, Hannah Deacon and Varinder Kaur, it aims to serve as a crucial resource for healthcare professionals, patients, and regulators seeking a deeper understanding of the use of CBMPs, particularly in patients with drug-resistant epilepsy.
Key topics covered include a detailed introduction to types, causes, and symptoms of epilepsy; how cannabinoids modulate brain pathways to reduce seizures; the evidence surrounding the use of THC in paediatric epilepsy; and potential interactions between CBMPs and epilepsy medications.
There is also a strong focus on real-world data and how patient-reported outcomes are shaping the future of epilepsy treatment.
Prof Barnes, co-founder of Maple Tree Consultants and the first doctor to obtain a license to prescribe cannabis in the UK, commented: “This publication offers an essential resource for clinicians, pulling together nearly 100 clinical trials, real-world studies, and case reports on the use of cannabis in epilepsy treatment. By compiling this extensive evidence, we provide a strong foundation for healthcare professionals to make informed decisions about the efficacy and safety of cannabis-based medicinal products.
“As medical cannabis continues to demonstrate its effectiveness in treating epilepsy in many patients, this guide is critical for advancing its acceptance and improving access for patients who need it most.”
The publication also provides in-depth analysis of the barriers faced by patients in accessing CBMPs within the UK’s regulatory framework, highlighting gaps in NHS access, the growing reliance on private clinics, and the financial strain families encounter when seeking treatment.
Hannah Deacon, Co-Founder of Maple Tree Consultants, whose successful campaign led to son Alfie’s doctors receiving the first schedule one licence to prescribe whole plant cannabis on the NHS, said: “For the first time, this publication pulls together the comprehensive evidence healthcare professionals need to better support children and families affected by epilepsy.
“My son Alfie’s life has been completely transformed by medical cannabis—from enduring hundreds of seizures a month to living a fuller, happier life. His journey is the reason I’m so passionate about advocating for children with refractory epilepsy. I truly hope this publication opens doors for many more families, giving clinicians the data they need to make informed decisions and improve access to this life-changing treatment.”
Co-author, Varinder Kaur, added: “Despite cannabis being legalised for medicinal use since 2018, patients are still struggling to access life-saving cannabis products via the NHS. Many doctors refuse to prescribe cannabis due to restrictive guidelines and concerns regarding the lack of evidence.
“Our publication provides an in-depth discussion on the preclinical and clinical evidence base of cannabis and epilepsy to help educate individuals from differing backgrounds. Cannabis is an effective therapy for children with severe treatment-resistant epilepsy and we hope that this publication can help support wider accessibility of cannabis medicines to epilepsy patients.”
Medical Cannabis & Epilepsy is the second publication in Maple Tree’s Medical Cannabis Evidence Base series and is available to purchase from the website.
The post New publication evidences role of medical cannabis in epilepsy appeared first on Cannabis Health News.
Continue reading...
